3D representation of the HTLV-1 intasome (a type of nucleoprotein complex) structure as visualized through cryo-electron microscopy. [Adobe Stock]
The topic of AI in drug discovery and development may continue to garner significant attention, but harnessing AI effectively requires a nuanced strategy, and an ability to navigate between details and the bigger picture.Andrew Anderson, vice president of innovation and informatics strategy at ACD/Labs, likens it to boiling water. “On a small scale, it’s straightforward. But boiling a tanker cart full of water? That’s a different ballgame,” he said.
Thinking through these aspects is vital to address the ‘pilot-purgatory’ problem, which frequently arises in projects involving emerging technology. As a growing number of drug developers launch proof-of-concept AI projects, a significant number are struggling to scale them. “There’s a stru…